They call it the “holy grail” of orthopaedics. What if it were possible to regenerate the cartilage that’s broken down by bone-on-bone arthritis?
Osteoarthritis, as you probably know, is what happens when the smooth surface of a joint gets damaged, either by injury or long-term wear-and-tear. It’s an irreversible process. Once lost, the knee can’t simply grow fresh cartilage to fill the gaps. The result is often years of problems with movement, stiffness, inflammation – and of course pain.
But now a new discovery at Stanford University promises to upend the traditional approach to arthritis treatment. They’ve found a therapy that stops damage and even restores healthy cartilage to arthritic knees. Is it a genuine breakthrough? And what are the implications for arthritis sufferers? Let’s look at the story in more detail…
What have the scientists discovered?
A research team from Stanford Medicine has developed a treatment that appears to reverse cartilage loss in ageing joints. In studies on mice, the therapy restored healthy cartilage to damaged knee joints, dramatically improving movement and function. When they applied the technique to human tissue samples taken from knee replacement surgeries, the cartilage began regenerating and forming new, functional cartilage after just one week.
Why can’t knee cartilage regrow on its own?
One of the key reasons is that articular cartilage – the type of cartilage that covers bone endings – lacks a blood supply (it’s avascular). Without blood vessels to deliver nutrients and repair signals, the damaged tissue has no way to heal itself. Meanwhile, inflammation increases. Inflammatory molecules begin to break down collagen, the main ingredient in cartilage. This causes the cartilage to become thinner and softer still.
How have doctors tried to fix this problem until now?
The current surgical approaches to cartilage loss centre on microfracture, transplantation and stem cell injections.
Microfracture – is a technique that involves making tiny holes in the bone surface beneath damaged cartilage. The holes encourage the bone to release bone marrow and stem cells, which form a clot that eventually rebuilds into a type of cartilage. (You can find out more about it here: Cartilage repair for knees: what is debridement and microfracture?)
Transplantation – is where healthy cells are transferred into the joint to encourage cartilage restoration. There are various methods of doing this, ranging from autografts (tissue transplanted from elsewhere in the body) to the MACI procedure (creating a lab-grown culture of cells before implanting them into the joint)
Stem cell injections * – is where the surgeon extracts cells from bone marrow or fat tissue, processes them in a lab to create a concentrate, and injects the solution into the joint where (theoretically) the cells can release growth factors and recruit the body’s natural repair mechanisms
* The evidence around stem cell treatment in knee arthritis is, unfortunately, somewhat inconclusive. A major 2025 review by the non-profit Cochrane network, for example, concluded that evidence is currently not strong enough to determine whether stem cell injections actually cause cartilage to regrow.
What’s wrong with the cartilage that current surgeries create?
The main problem is that it’s not true hyaline cartilage (hyaline cartilage is the proper name for articular cartilage). There are actually three main types of cartilage in the body:
Elastic – the most flexible type, found in structures like the epiglottis and outer ear
Fibrocartilage – a tough form of cartilage found in structures like joint capsules and the spine
Hyaline – thin, glassy, hard-wearing tissue that’s designed for friction-free movement between bones
The current techniques, when successful, generate fibrocartilage. Fibrocartilage is tough and scar-like but it doesn’t possess the same shock-absorbent and friction-reducing qualities as original hyaline cartilage. It’s more like a patch than true restoration.
How does the new treatment work?
It takes a completely different approach to the problem. Rather than stimulating cell growth or transplanting cells, it targets the ageing process itself. As we age, our bodies produce increasing amounts of a protein called 15-PGDH. Researchers call this substance a “gerozyme”; basically, an ageing enzyme. The problem with 15-PGDH is that it breaks down another complicated-sounding substance known as prostaglandin E2, a compound that plays an important part in tissue repair. By using a small ‘inhibitor’ molecule to block the 15-PGDH, the scientists thought they might be able to prevent the breakdown.
What effect did they see in knee joints?
It was dramatic. When the blocking molecule was administered, prostaglandin E2 levels began to rise again. The cartilage didn’t merely stop weakening – it actually began to thicken and regenerate. Cartilage cells that were already in the joint started to change their behaviour. They shifted away from breaking down collagen, and instead acted like younger cells. “The gerozyme inhibitor causes a dramatic regeneration of cartilage beyond that reported in response to any other drug or intervention,” orthopaedic surgeon Nidhi Bhutani, one of the researchers, explained to Science Daily. “The effect was remarkable.”
Did it create real knee cartilage?
The Stanford treatment produced genuine hyaline cartilage, not the inferior fibrocartilage. The therapy also showed dramatic effects in preventing arthritis after injuries. Mice with knee injuries resembling ACL tears that received the treatment were far less likely to develop osteoarthritis. They also moved more normally and placed more weight on the injured leg compared to untreated animals.
Has this been tested in humans yet?
The treatment has been tested on human tissue, but not yet in living patients. The researchers applied the treatment to cartilage samples taken from patients undergoing total knee replacement for osteoarthritis. After one week of treatment, the tissue showed:
- Fewer cells producing the ageing enzyme 15-PGDH
- Reduced expression of cartilage degradation genes
- Early signs of articular cartilage regeneration
- While this is encouraging, it’s important to understand that growing tissue in a laboratory dish is very different from regenerating cartilage inside a living, weight-bearing human knee joint. Needless to say, mouse biology doesn’t perfectly mirror human joint mechanics.
What are the limitations we need to know about?
While this research is very exciting, there are several important caveats:
Human testing was in the lab, not in people: The human cartilage samples that responded to treatment were tested outside the body in a laboratory setting. Real-world conditions inside a living joint are much more complex.
No human clinical trials yet for cartilage: While the researchers hope to launch trials “soon,” the treatment hasn’t yet been tested in actual arthritis patients. It’s currently not approved or available for cartilage regeneration.
The inflammation paradox: The treatment works by raising levels of prostaglandin E2, which is typically associated with inflammation and pain. The researchers believe that small increases at normal biological levels promote regeneration rather than causing problems, but this will need careful monitoring in human trials.
“Environment” is crucial: It’s important to remember that joint-surface damage is rarely the only issue at stake in osteoarthritis. Often, the damage is caused by a mechanical problem, such as malalignment, which puts grinding pressure on one specific portion of the knee. In this scenario, any new substance or regrown cartilage introduced to the joint is likely to wear away again just like the original tissue, unless the underlying mechanical environment is also addressed.
When might this treatment be available to patients?
The honest answer is that the treatment is likely still years away from becoming available to patients. While Phase 1 clinical trials of a 15-PGDH inhibitor have shown the drug is safe and active in healthy volunteers, those trials focused on muscle weakness, not joint cartilage. The researchers expressed hope that a trial for cartilage regeneration will be launched soon, but moving from promising lab results to an approved treatment typically takes several years.
Reasons for hope?
Absolutely. The Stanford research is really encouraging. In fact, in the long run, it could represent a paradigm shift in the way doctors approach osteoarthritis – from focusing on symptom management and pain reduction to addressing the root cause of cartilage loss. We may be some way off from that kind of reality, but recent developments suggest scientists are getting closer. As Professor Helen Blau, Senior author of the research, puts it: “Our hope is that a similar trial [to the original Phase 1 study] will be launched soon to test its effect in cartilage regeneration. We are very excited about this potential breakthrough. Imagine regrowing existing cartilage and avoiding joint replacement.”
Read up on the latest scientific discoveries
The Stanford research isn’t the only piece of research that has been making waves in orthopaedic medicine recently. Here are some other developments that are worth keeping an eye on…
- A “game-changing” treatment for knee arthritis pain?
- How an “electronic knee sleeve” from Hampshire is helping patients tackle knee pain
- The “rubbery goo” that could provide an alternative to knee replacements
- Can weight loss drugs like Wegovy reduce arthritis knee pain?
- Could a “dissolvable wafer” revolutionise pain relief for knee replacements?
